Scholarlink

<p>The fundamental reason in chemotherapy’s failure to treat breast cancer (BC) is therapy confrontation. BC is frequently treated with anastrozole (ANZ), a non-steroidal aromatase inhibitor. But, its incomplete bioavailability and side effects necessitate improved drug delivery system. This study intended to increase the cytotoxicity impact of ANZ by loading it in polymeric nanocapsules (ANZ-PNCs) in MCF-7 via increasing IC<sub>50</sub> and apoptosis. Polymeric nanocapsules (PNCs) prepared using an emulsion-based method, And particle dimension and morphology were characterized via field emission scanning electron microscopy (FESEM) and dynamic light scattering (DLS). UV-vis spectroscopy was used to measure the encapsulation efficiency (E.E.%) of ANZ-loaded PNCs. Apoptosis induction was assessed by Flow Cytometry, Anexxin V-FITC/PI labeling, BAX, P53, BCL-2 genes using real-time PCR, and caspase-3,-8, and − 9 activity assays. The synthesized ANZ-PNCs showed a uniform spherical shape with an average size 10&#xa0;nm. Drug loading content (LC%) was 3.2 ± 0.4 and the EE% was 74.6 ± 2.3. In vitro cytotoxicity assay by MTT test revealed ANZ-loaded PNCs (9&#xa0;µg/mL) achieved similar therapeutic effects than free ANZ (48&#xa0;µg/mL). <i>BAX</i> and <i>P53</i> expression significantly increased (3.3 (<i>P</i> &lt; 0.01) and 2.8 (<i>P</i> &lt; 0.05) times, respectively); contrarywise, <i>BCL-2</i> was decreased versus untreated controls. Caspase-3, and − 9 levels (<i>P</i> &lt; 0.001) and caspase − 8 (<i>P</i> &lt; 0.01) were elevated after ANZ-loaded PNCs administration. Morphological studies revealed nuclear fragmentation and cell shape changes after giving 9&#xa0;µg/mL ANZ-PNCs, indication apoptosis induction. Strong matches, the ANZ loaded PNCs can be used to deliver ANZ for breast cancer chemotherapy of breast cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antineoplastic effect of anastrozole-loaded polymer nanocapsules on malignant human breast cancer cells (MCF-7)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月1日

查看全文
  • Pooneh Nikouei,
  • Gholamreza Motalleb,
  • Abass Rahdar,
  • Rahim Nosrati

摘要

The fundamental reason in chemotherapy’s failure to treat breast cancer (BC) is therapy confrontation. BC is frequently treated with anastrozole (ANZ), a non-steroidal aromatase inhibitor. But, its incomplete bioavailability and side effects necessitate improved drug delivery system. This study intended to increase the cytotoxicity impact of ANZ by loading it in polymeric nanocapsules (ANZ-PNCs) in MCF-7 via increasing IC50 and apoptosis. Polymeric nanocapsules (PNCs) prepared using an emulsion-based method, And particle dimension and morphology were characterized via field emission scanning electron microscopy (FESEM) and dynamic light scattering (DLS). UV-vis spectroscopy was used to measure the encapsulation efficiency (E.E.%) of ANZ-loaded PNCs. Apoptosis induction was assessed by Flow Cytometry, Anexxin V-FITC/PI labeling, BAX, P53, BCL-2 genes using real-time PCR, and caspase-3,-8, and − 9 activity assays. The synthesized ANZ-PNCs showed a uniform spherical shape with an average size 10 nm. Drug loading content (LC%) was 3.2 ± 0.4 and the EE% was 74.6 ± 2.3. In vitro cytotoxicity assay by MTT test revealed ANZ-loaded PNCs (9 µg/mL) achieved similar therapeutic effects than free ANZ (48 µg/mL). BAX and P53 expression significantly increased (3.3 (P < 0.01) and 2.8 (P < 0.05) times, respectively); contrarywise, BCL-2 was decreased versus untreated controls. Caspase-3, and − 9 levels (P < 0.001) and caspase − 8 (P < 0.01) were elevated after ANZ-loaded PNCs administration. Morphological studies revealed nuclear fragmentation and cell shape changes after giving 9 µg/mL ANZ-PNCs, indication apoptosis induction. Strong matches, the ANZ loaded PNCs can be used to deliver ANZ for breast cancer chemotherapy of breast cancer.